Nextcure presents non-clinical data defining the mechanism of nc525 at the 2023 federation of clinical immunology societies (focis) annual meeting

Beltsville, md., june 21, 2023 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of a poster that defines the mechanism of nc525-induced apoptosis of leukemic cells, but not healthy hematopoietic cells, at the federation of clinical immunology societies (focis) annual meeting in boston. nc525 is a humanized monoclonal antibody (mab) that specifically binds to lair-1 and is being developed for the treatment of advanced myeloid leukemias, including acute myeloid leukemia (aml), myelodysplastic syndrome and chronic myelomonocytic leukemia (cmml).
NXTC Ratings Summary
NXTC Quant Ranking